Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CT-0508 in HER2 Overexpressing Solid Tumors
NCT04660929Phase 1Active, not recruiting
- Sponsor
- Carisma Therapeutics
- Start
- Feb 2021
- Primary completion
- Dec 2024
- Modality
- Gene Editing, Prophylactic Vaccines, Gene Silencing
- Countries
- 1
01
Overview
Phase 1, open-label trial of CT-0508 in HER2-positive solid tumor (4 arms), sponsored by Carisma Therapeutics. Primary endpoints: Adverse Events at 14 months, Manufacturing Feasibility at 12 months and 1 more. Started Feb 2021; status: active, not recruiting.
02
Drugs
CT-0508
03
Conditions
HER2-positive solid tumor
Beyond the preview
Go deeper on NCT04660929.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04660929.